| Similar Articles |
|---|
 |
The Motley Fool
May 15, 2007
Mike Havrilla |
A Tale of Two Trials at YM Bio Encouraging results and ongoing drug trials give YM BioSciences' investors hope.   |
BusinessWeek
February 13, 2006
Gene G. Marcial |
YM Biosciences' Cancer Drugs Are Working Tiny biotech, YM Biosciences, trading on the Amex, may have a winner: Tesmilifene for metastatic breast cancer. |
The Motley Fool
January 25, 2008
Brian Lawler |
What's Not to Like About Gilead? Gilead is looking more and more like a diversified pharma with a robust clinical-stage pipeline and growing cash flows. |
The Motley Fool
December 21, 2010
Brian Orelli |
Our Drug Is Better Than Your Drug Without a question, Incyte's compound, INCB18424, works in myelofibrosis. Now that it has positive phase 3 results, it's time to get a brand name for the thing; INCB18424 just isn't that catchy. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
February 27, 2007
Brian Lawler |
Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors. |
The Motley Fool
December 20, 2010
Brian Orelli |
A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
The Motley Fool
December 13, 2011
David Williamson |
3 Biotechs Making Big Moves on Big News Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
May 18, 2011
Brian Orelli |
5 Biotech ASCO Abstracts to Watch The biotech investors' Christmas in May is once again upon us, where investors and researchers alike will be able to find the synopsis of what will be presented at the American Society of Clinical Oncology annual meeting next month. |
The Motley Fool
March 31, 2011
Brian Orelli |
Gilead's Long-Term Cancer Fight An academic partnership is a good sign it's serious. |
The Motley Fool
June 25, 2010
Brian Orelli |
Diversification Times 50,000 Gilead Sciences diversifies any way it can. |
The Motley Fool
December 16, 2009
Brian Orelli |
Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising. |
The Motley Fool
May 4, 2007
Mike Havrilla |
On Deck in Biotech Investors can keep an eye on possible catalysts for these stocks in the next week: YM BioSciences... DOR BioPharma... IDM Pharma's... etc. |
The Motley Fool
June 12, 2008
Brian Lawler |
Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright. |
The Motley Fool
February 23, 2011
Brian Orelli |
Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug. |
BusinessWeek
April 25, 2005
Sarah Lacy |
BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche |
The Motley Fool
June 29, 2005
Karl Thiel |
Cash In on the Future of Science With some diligence, you can ride your high school biology to biotech investing success. |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
Pharmaceutical Executive
September 1, 2010 |
Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days? |
The Motley Fool
July 21, 2006
Brian Lawler |
Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet. |
Chemistry World
September 2010 |
Column: In the pipeline Derek Lowe considers the quandaries of living in the age of the kinase |
The Motley Fool
May 30, 2008
Brian Lawler |
Gilead Gets Synergistic Gilead Sciences newly acquired compound will play nicely with the drugmaker's existing products. |
Pharmaceutical Executive
December 1, 2013 |
Country Report: Canada Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D and leverage its geographic reach in the North American Market. |
The Motley Fool
September 6, 2007
Brian Lawler |
Foolish Fantasy Football: Gilead Sciences on Offense For his fantasy football investment team, this stock analyst thinks Gilead packs enough offensive muscle to score in anyone's portfolio. |
The Motley Fool
July 30, 2004
Roger Nusbaum |
Gilead Keeps Rolling Along Biotech can be a tough place to invest, but Gilead Sciences offers relative stability. |
The Motley Fool
November 28, 2011
David Williamson |
5 Biotechs Posting Big Gains The daily health-care news investors need to read. |
BusinessWeek
February 19, 2007
Arlene Weintraub |
How Gilead Primed The Pipeline Gilead's $2.5 billion purchase of Myogen offers instant diversification from its HIV drug focus. |
The Motley Fool
July 27, 2011
Brian Orelli |
Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain. |
The Motley Fool
May 19, 2004
Roger Nusbaum |
Gilead Shines This biotech company looks strong because investors can relate to its products. |
The Motley Fool
October 2, 2006
Brian Gorman |
Gilead's Smart Risk The drug developer's latest purchase is a risk, but it's a well-calculated one. Investors, take note. |
The Motley Fool
November 17, 2011
Brian Orelli |
In Biotech, Approval's Important, but It's the Launch That Counts With an approval in hand, Incyte's investors are still nervous. |
The Motley Fool
January 6, 2010
Brian Orelli |
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. |
The Motley Fool
September 20, 2011
Brian Orelli |
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? |
The Motley Fool
December 31, 2007
Brian Lawler |
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
July 18, 2008
Brian Lawler |
Still Liking Gilead, Warts and All Don't look past a few issues, even though Gilead still has a bright future. |
The Motley Fool
July 22, 2009
Brian Orelli |
Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences. |
The Motley Fool
September 19, 2008
Brian Lawler |
FDA Tells Gilead to Take 1 More Step There's a small consolation prize for Gilead Sciences in this rejection from the FDA. |
The Motley Fool
April 3, 2009
Brian Orelli |
Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker. |
The Motley Fool
October 7, 2011
Brian Orelli |
A Little Help, Please Gilead pumps up the pipeline. |
